Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × siremadlin × Other hematologic neoplasm × Clear all

Phase

Status

Sponsor Class

INDUSTRY 4 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1 Sarcoma 1 Other hematologic neoplasm 1 Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 594 Cytarabine 512 fludarabine 351 fludarabine phosphate 343 venetoclax 271 Rituximab 256 Methotrexate 256 Azacitidine 235 Busulfan 209 Etoposide 195 Whole-Body Irradiation 193 Filgrastim 189 Peripheral Blood Stem Cell Transplantation 180 Mycophenolic Acid 178 Dexamethasone 164 Tacrolimus 159 Melphalan 155 Vincristine 150 Granulocyte Colony-Stimulating Factor 148 Decitabine 146 Cyclosporine 131 Daunorubicin 121 Idarubicin 120 Antilymphocyte Serum 117 Imatinib Mesylate 113 Lenalidomide 102 Radiotherapy 100 Doxorubicin 99 Stem Cell Transplantation 97 Mitoxantrone 93

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04496999 2022-10-06

HDMM

Insel Gruppe AG, University Hospital Bern

Phase 1 Terminated

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡